Evicenter
P&T meetings

Zanzalintinib (XL092)

Metastatic colorectal cancer

Manufacturer
Exelixis
Regulatory submission
NDA submitted December 2025
Launch
Not announced
Last updated
65 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

EGFR monoclonal antibodies

2 evidence topics · 2 sources

Biomarker-directed treatment recommendations

“Anti-EGFR therapy is not recommended for patients with RAS-mutant mCRC.” (opens the source at this quote in a new tab)

Population recommended for first-line anti-EGFR therapy plus doublet chemotherapy

“MSS or pMMR left-sided RAS wild-type mCRC” (opens the source at this quote in a new tab)